Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific director transaction rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported. The filing details a specific administrative event: a revaluation of the cash element of the notional investment held within the US Retirement Savings Plan, which is notionally held in GSK American Depositary Shares (ADSs).
Management Commentary and Risks
The Administrators of the Plan notified GlaxoSmithKline plc and the relevant director on March 4, 2013, of an increase in the notional allocation of ADSs on March 1, 2013. The transaction occurred at a price of $44.22 per ADS. No broader outlook, risks, or contingencies are discussed in this specific filing.
Important Facts for Investors
- Transaction Type: Notification of a notional increase in ADS allocation within the US Retirement Savings Plan.
- Director Involved: Dr. M. M. Slaoui.
- Quantity: 19 ADSs.
- Price: $44.22 per ADS.
- Date of Notification: March 4, 2013.
- Regulatory Basis: Disclosure and Transparency Rule 3.1.4R(1)(a).